The National Institute for Health and Care Excellence (NICE) has recommended Sanofi Genzyme’s Jevtana (cabazitaxel), in combination with prednisone or …
The National Institute for Health and Care Excellence (Nice) has backed three drugs for the treatment of type 2 diabetes. …

The National Institute for Health and Care Excellence (Nice) has recommended Novartis’ (VTX: NOVN) Ceritinib (zykadia) as a treatment for …

The National Institute for Health and Care Excellence (Nice) has provisionally turned down Swiss drugmaker Roche’s (VTX: ROG) breast cancer …
A new UK governmental report has warned that the global rise of antimicrobial resistance is set to worsen, with the …
The Patients Association has called on all Clinical Commissioning Groups (CCGs) to implement the National Institute for Health and Care …
The National Institute for Health and Care Excellence (Nice) has backed two blood tests to help rule-out a complication in …

The National Institute for Health and Care Excellence (Nice) has backed GlaxoSmithKline’s (LSE: GSK) Benlysta (belimumab) to treat lupus. The …
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …
UK regulators have extended the cost negotiation talks with PTC Therapeutics (Nasdaq: PTCT) by a week for the drug to …

The National Institute for Health and Care Excellence (NICE) on Friday backed a combination therapy for skin cancer comprising two …
The National Institute for Health and Care Excellence (NICE) has backed Bristol-Myers Squibb’s paclitaxel as a treatment for ovarian cancer. …

NICE has published final guidance recommending heart failure drug Entresto (sacubritil/valsartan). The drug, developed by Novartis, has performed well in …

The ABPI has welcomed the findings of a National Audit Office report on the commission of specialised service by NHS …

Prostate cancer treatment Jevtana (cabazitaxel), marketed by Sanofi (NYSE: SNY) has been recommended by NICE in its final guidance. The …